Memorial Sloan Kettering Cancer Center

https://www.mskcc.org/healthcare-professionals

Refer a Patient to MSKCC: mskcc.org/refer

 

Cleveland Clinic's 20th Annual ASH Review
A

2019 ASH Review on Combinations or Sequences of Targeted Agents in CLL: Ibrutinib + Venetoclax for the 1st-Line Treatment - Should MRD Status at EOT Be Driving Treatment Decisions?

By Cleveland Clinic's 20th Annual ASH Review FEATURING Anthony R. Mato
By Cleveland Clinic's 20th Annual ASH Review FEATURING Anthony R. Mato
78 views
April 14, 2020
Comments 0
Login to view comments. Click here to Login

Featured Video

08:44
Johnson & Johnson

Management and Proactive Care of Adverse Events Associated with Loca…

Feat. J. Sabari, A. Spira

Featured Video

21:24
Exelixis

Hypothetical Patient Case: Hepatocellular Carcinoma with Progression…

Feat. J. Gutierrez, J. Strauss
Leukemia
18:42

Key Updates in AML, MDS, & MF From ASH

Memorial Sloan Kettering Cancer Center

A. Goldberg

298 views
15:23

SOHO 2023: Updates on the Role of SCT in ALL in the Era of CAR-T

SOHO 2023 Eleventh Annual Meeting

J. Park

83 views
13:15

SOHO 2023 Menin Inhibition for KMT2A-Rearranged ALL

SOHO 2023 Eleventh Annual Meeting

E. Stein

39 views
30:21

ASH 2022 Highlights on CML: Clinical Overview From iCMLf

International CML Foundation

M. Mauro

112 views
04:55

ASH 2022 Initial Results From SELECT-AML-1: a Phase 2 Study of Tamib…

ASH 2022 Conference Coverage

E. Stein

167 views
04:22

EHA 2022 Tamibarotene in Combination With Ven & Aza in Previously Un…

EHA 2022 Conference Coverage

E. Stein

206 views
54:58

Expert Perspectives on Treating High-Risk and R/R AML

PleXus Communications

E. Stein

141 views
04:36

Safety & Efficacy of Asciminib for Heavily Pretreated Patients With …

ecancer

M. Mauro

26 views
05:49

ASH 2021 Update on the Safety & Efficacy of Menin Inhibition in MLL-…

ASH 2021 Conference Coverage on VuMedi

E. Stein

130 views
16:42

IDH Inhibitors in Myeloid Malignancies: What Are the Mechanisms of R…

University of Miami's 2nd Biennial Miami Leukemia Symposium

E. Stein

228 views
06:19

2019 ASH Review of Frontline CLL: Is There a Role for FCR in 2020 an…

Cleveland Clinic's 20th Annual ASH Review

A. Mato

343 views
07:59

2019 ASH Review of Frontline CLL: Can We Improve CIT by Adding a Nov…

Cleveland Clinic's 20th Annual ASH Review

A. Mato

174 views
05:08

2019 ASH Review on Combinations or Sequences of Targeted Agents in C…

Cleveland Clinic's 20th Annual ASH Review

A. Mato

78 views
04:52

2019 ASH Review on Venetoclax in the R/R CLL: With Additional Follow…

Cleveland Clinic's 20th Annual ASH Review

A. Mato

27 views
08:21

2019 ASH Review on Overcoming BTKi Resistance in CLL: Era of Non-Cov…

Cleveland Clinic's 20th Annual ASH Review

A. Mato

32 views
15:19

29 y/o Male w/ CML: Allograft vs. 3rd Line Therapy - Transplant Is A…

Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

M. Mauro

16 views
15:59

New Kinase Inhibitors for CML: Asciminib, PF-114, & HQP1351

Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

M. Mauro

29 views
27:00

Acute Myeloid Leukemia - Overview of Available Novel Agents with Uni…

Indy Hematology Review

M. Tallman

1.8K views
07:46

Oral Abstract CML-044: Treatment-Free Remission (TFR) in Patients wi…

Society of Hematologic Oncology Sixth Annual Meeting (SOHO 2018)

M. Mauro

16 views
17:58

Front-line Strategies in Ph-negative ALL

Memorial Sloan Kettering Cancer Center

M. Geyer

172 views
13:41

Updates and Challenges in the Management of Chronic Myeloid Leukemia…

Memorial Sloan Kettering Cancer Center

M. Mauro

146 views
17:13

Multi-drug Resistant and Intolerant CML: What to Do?

Memorial Sloan Kettering Cancer Center

M. Mauro

168 views
08:42

IDH Inhibitors in AML

Memorial Sloan Kettering Cancer Center

E. Stein

166 views